STAAR Surgical (STAA) Q1 2026 earnings review
China Destocking Hangover Clears, But Margins and Transparency Remain Cloudy
STAAR Surgical delivered a massive 119.6% YoY revenue surge to a record $93.5M, officially signaling the end of its brutal 2025 China destocking phase. The volume recovery pushed the company back into the black, reversing a massive year-ago loss into $5.2M of Net Income. However, the optics of the +120% growth mask a harsh reality: ex-China sales grew a sluggish 6.0%. While the U.S. market is accelerating beautifully (+22%), weakness in EMEA and geopolitical headwinds are acting as an anchor. More concerningly, management explicitly refused to provide formal numerical guidance for FY26 and warned that gross margins will be lower than last year due to the costs of bringing their new Swiss plant online.
🐂 Bull Case
The massive channel inventory overhang that destroyed 2025 earnings is resolved. With distributors at or below contractual levels, reported sales will now match true in-market retail demand.
U.S. sales surged 22% YoY, eclipsing $6M for the quarter. The recently expanded FDA indication (ages 45-60) is unlocking a new demographic against a backdrop of declining laser-based procedures.
🐻 Bear Case
Despite claiming the Alcon merger disruption is in the 'rearview mirror', management still refuses to issue formal financial guidance, making it impossible to confidently model 2026 earnings.
While the Americas grew 26%, total ex-China growth was a meager 6%. Geopolitical issues in the Middle East and India are creating drag, proving the company remains heavily over-reliant on China.
⚖️ Verdict: ⚪
Neutral. The operational turnaround is real—the China channel is fixed and cost discipline has returned. However, an investment thesis requires numbers, and management's refusal to guide, combined with explicit warnings of impending gross margin compression, keeps this in the 'show me' penalty box.
Key Themes
China Returns to Driving Growth
Reversing the catastrophic declines of early 2025, APAC revenue skyrocketed to $72.3M. More importantly, the launch of the new EVO+ ICL in China is exceeding early expectations. Because EVO+ carries a premium price tag, it should serve as a powerful ASP driver as adoption scales throughout the year.
U.S. Operations Accelerating
The Americas segment was the standout performer outside of the China base-effect rebound. U.S. net sales accelerated 22% YoY. As laser-based vision correction continues a multi-year double-digit decline, STAAR is successfully positioning the Collamer lens as the premium, reversible alternative, aided by the new FDA age indication expansion.
Swiss Plant Shields Against Tariffs
Management confirmed that the Nidau, Switzerland facility will supply 100% of the EVO and EVO+ ICLs shipped to China in 2026. This permanently removes the existential threat of U.S.-China tariffs that forced the company into risky consignment inventory maneuvers last year.
Ex-China Growth Contradicts Global Strength Narrative
Decelerating. Management frequently pitches a massive global total addressable market, but the data tells a narrower story. Ex-China sales grew just 6.0% to $46.1M. With the Americas growing 26%, this implies that EMEA and the rest of APAC are effectively flat or negative. Management blamed $2M of the shortfall on geopolitical disruptions in the Middle East and India.
Gross Margin Set to Compress
Decelerating. Q1 Gross Margin looked fantastic on a YoY basis (73.6% vs 65.8%), but that is a flawed comparison against a restructuring quarter. Management explicitly guided that FY26 Gross Margin will be 'slightly lower' than FY25's 76.2%. The culprit: selling higher-cost inventory manufactured at the newly ramped Swiss facility, combined with increased reserves for expiring legacy products.
Lack of Financial Guidance
Stable. The company withdrew guidance in mid-2025 during the Alcon merger chaos. Now that the merger is dead and the China inventory is allegedly fixed, the refusal to reinstate formal numerical guidance for FY26 signals that management either lacks visibility into consumer demand in China or fears further macroeconomic shocks.
Other KPIs
Reversing. A massive swing from the $(26.3) million loss in 25Q1. This highlights the severe operating leverage inherent in STAAR's business model. When sales cratered last year, margins collapsed; as volume returns, cash flow generation is explosive.
Decelerating. Operating expenses dropped 18.0% YoY, proving that the harsh cost-cutting initiatives enacted by the interim leadership team in H2 2025 are structurally sticking. General & Administrative expenses alone plummeted 30% to $17.0M.
Guidance
Decelerating. FY25 gross margin was 76.2%. The drop is attributed to the absorption of higher per-unit costs from the new Swiss manufacturing facility and inventory obsolescence reserves. This means the top-line recovery will not flow through to the bottom line as efficiently as historical norms.
Stable. Management intends to hold the line on the aggressive cost cuts implemented in 2025. If revenue continues to scale while OpEx remains artificially capped at 2023 levels, it will generate immense operating leverage.
Reversing. Following a devastating FY25 that saw a net loss of over $80 million (heavily impacted by restructuring and merger fees), the company expects to be profitable for the full year 2026. However, they refused to provide an EPS range.
Key Questions
Path to Reinstating Guidance
You stated the China channel is clean and the Alcon disruption is behind you, yet you refused to provide FY26 numerical guidance. What specific macroeconomic or operational indicators do you need to see before you feel confident enough to provide a formal outlook to the Street?
Swiss Facility Margin Drag
You noted that selling higher-cost Swiss inventory will act as a drag on FY26 gross margins. At what production volume run-rate does the Swiss facility reach cost-parity with your U.S. manufacturing footprint?
Ex-China Growth Stagnation
Excluding the Americas and China, the rest of the world appears to be flat or declining. Besides the sub-$2M geopolitical impacts mentioned, what is structurally slowing down the EMEA and broader APAC regions, and how are you adapting commercial strategies there?
EVO+ ASP Premium
Can you quantify the Average Selling Price (ASP) premium that EVO+ is commanding in China relative to the legacy EVO lens, and how quickly do you expect it to cannibalize the older product mix?